Synonyms: ZE46-0134
Compound class:
Synthetic organic
Comment: Lomonitinib is the INN for a tyrosine kinase inhibitor with antineoplastic potential. It appears to be the INN for Eilean Therapeutics' pan-FLT3/IRAK4 inhibitor (ZE46-0134) that is designed to simultaneously target clinically relevant resistance and activating FLT3 mutations and putative escape pathways (that arise via activation of IRAK4) in advanced AML [1].
|
|
Bioactivity Comments |
At time of writing (Feb 2024) we have been unable to find any quantitative data that supports the compound's interaction with primary molecular target(s) or mechanism of action. |